11.225  -0.275 (-2.39%)		12-05 11:03
Open: 11.38 High: 12.095 Volume: 38,473		Pre. Close: 11.5 Low: 11.2 Market Cap: 463(M)

Short term
Mid term
Targets	6-month :	14.02	1-year :	15.48
Resists	First :	12	Second :	13.25
Pivot price	11.18
Supports	First :	9.98	Second :	8.3
MAs	MA(5) :	11.52	MA(20) :	11.32
	MA(100) :	14.56	MA(250) :	14.67
MACD	MACD :	-0.3	Signal :	-0.4
%K %D	K(14,3) :	62.9	D(3) :	57.9
RSI	RSI(14): 46.9
52-week	High :	24.79	Low :	3.63

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ELVN ] has closed below upper band by 37.7%. Bollinger Bands are 32.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	11.88 - 11.94	11.94 - 11.99
Low:	11.08 - 11.14	11.14 - 11.19
Close:	11.41 - 11.51	11.51 - 11.59

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Thu, 09 Nov 2023
Enliven Therapeutics Reports Third Quarter 2023 Financial Results ... - Yahoo Finance

Mon, 06 Nov 2023
Enliven Therapeutics Insider Sold Shares Worth $111751 ... - Marketscreener.com

Mon, 23 Oct 2023
ESMO 2023: New approaches to old targets, including HER2 and p53 - BioWorld Online

Thu, 17 Aug 2023
7 A-Rated Biotech Stocks for Your August Buy List - InvestorPlace

Thu, 10 Aug 2023
Fairmount Funds Management LLC Acquires New Stake in Kiniksa ... - Yahoo Finance

Tue, 23 May 2023
Peter Kolchinsky-led RA Capital's New Positions Feature CureVac ... - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	41 (M)
Shares Float	11 (M)
Held by Insiders	7 (%)
Held by Institutions	85.9 (%)
Shares Short	5,220 (K)
Shares Short P.Month	5,100 (K)

EPS	-0.93
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.34
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-23.9 %
Return on Equity (ttm)	-36 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.69
Qtrly Earnings Growth	0 %
Operating Cash Flow	-57 (M)
Levered Free Cash Flow	-31 (M)

PE Ratio	-12.4
PEG Ratio	0
Price to Book value	1.79
Price to Sales	0
Price to Cash Flow	-8.26

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.